Bharat Biotech on course to have 26,000 volunteers for Phase-3 clinical trials of Covaxin
Posted by
www.biotecnika.org
The company statement has come after an expert panel of India's
central drug authority recommended granting permission for restricted
use of Covaxin in emergency situation, especially in the context of
infection by mutant strains.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-on-course-to-have-26000-volunteers-for-phase-3-clinical-trials-of-covaxin/articleshow/80076123.cms
Subscribe to:
Post Comments (Atom)
Post a Comment